March 15, 2023
Astellas Pharma said on March 14 that its androgen receptor inhibitor Xtandi (enzalutamide) in combination with hormone therapy achieved the main goal in a Chinese PIII study for men with metastatic hormone-sensitive prostate cancer (HSPC). The company plans to seek...read more